AbbVie Reports Phase 3 Results for Navitoclax Plus Venetoclax in Relapsed/Refractory CLL

AbbVie today announced results from the Phase 3 trial evaluating navitoclax, a BCL-2/BCL-XL inhibitor, in combination with venetoclax plus rituximab versus venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. The triple combination demonstrated a statistically significant improvement in progression-free survival with a hazard ratio of 0.58. The safety profile was manageable with thrombocytopenia being the most common adverse event, consistent with BCL-XL inhibition. These results support navitoclax combinations as a potential new treatment approach for relapsed/refractory CLL.